Register now for our first webinar for 2025!
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality and morbidity in Australia.1 Low density lipoprotein cholesterol (LDL-C) is a key causal factor in this pathological process and the primary target in the secondary prevention of ASCVD.2 Despite the widespread uptake of LDL-C lowering medications, many patients remain at increased risk of future CV events even after achieving guideline-recommended levels of LDL-C.3 This is commonly referred to as residual risk.3
Presented by Dr Robert Hungerford and Assoc. Prof Adam Nelson, this webinar will explore how to perform an advanced cardiovascular risk assessment to better stratify a patients’ cardiovascular risk, and to how to address residual risk with individualised treatments for important non-lipid risk factors, such as obesity.
Date: Thursday, 13 February 2025
7:00pm - 8:30pm AEDT
6.00pm - 7.30pm AEST
6:30pm - 8:00pm ACDT
5:30pm - 7.00pm ACST
4:00pm - 5:30pm AWST
References
- Australian Institute of Health and Welfare. 2023. Heart, stroke and vascular disease: Australian facts. Available at www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/about (accessed January 2024).
- National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand. Australian clinical guidelines for the management of acute coronary syndromes 2016. Heart Lung Circ. 2016;25(9):895-951
- Matsuura Y, Kanter JE, Bornfeldt KE. Highlighting Residual Atherosclerotic Cardiovascular Disease Risk. Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):e1-e9.
Speakers
Dr Hungerford is a Fellow of the RACGP and was awarded the Tony Buhagiar Medal in 2014. He is GP supervisor in a large teaching general practice in Newcastle, also working at a rapid access GP clinic at the John Hunter Hospital. He is conjoint lecturer at the university of Newcastle and is regularly involved with education at a regional and national level in his areas of interest, namely ASCVD, Heart failure and diabetes.
Assoc. Prof Nelson is an early career interventional cardiologist and clinical triallist with academic and clinical interests in dyslipidaemia, obesity and diabetes.
